Patients with cancer demonstrate an increased vulnerability for infection and severe disease
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …

HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality.
Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing …

With the outbreak and pandemic of coronavirus disease‐2019 (COVID‐19), a huge number
of people died of it. Apart from lung injuries, multiple organs have been confirmed to be …

Introduction A high incidence of mortality and severe COVID‐19 infection was reported in
hematopoietic stem cell transplant (HSCT) recipients during the early phases of the COVID …

Covid-19 vaccination is recommended in allogeneic transplant recipients, but many
questions remain regarding its efficacy. Here we studied serologic responses in 145 patients …

Monoclonal antibodies for prophylaxis and treatment of respi... : Current Opinion in Infectious
Diseases Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections …

Immunogenicity of SARS-CoV-2 vaccination is diminished in hematopoietic stem cell
transplant (HSCT) recipients. To summarize current evidence and identify risk factors for …

In the current post-pandemic era, recipients of an allogeneic hematopoietic stem cell
transplant (HCT) deserve special attention. In these vulnerable patients, vaccine …

We aimed to identify the severity and duration of COVID-19 infection on complications after
allo-HSCT. Enrolled 179 hospitalized patients with COVID-19 were categorized into long …

Background Hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T‐cell
therapy (CAR‐T) recipients are at higher risk of serious complications of COVID‐19 infection …